It is made available under a CC-BY-NC-ND 4.0 International license .

A germline heterozygous dominant negative *IKZF2* variant causing syndromic primary immune regulatory disorder and ICHAD

Henry Y. Lu^{1,2}, Maryam Vaseghi-Shanjani^{1,2}, Avery J. Lam^{3,4}, Mehul Sharma^{1,2}, Arezoo
Mohajeri⁵, Jana Gillies^{3,4}, Gui Xiang Yang⁵, Susan Lin¹, Maggie P. Fu^{5,6,7}, Areesha
Salman⁵, Ronak Rahmanian⁸, Linlea Armstrong⁵, Jessica Halparin^{1,9}, Connie L. Yang^{1,9},
Mark Chilvers^{1,10}, Erika Henkelman¹¹, Wingfield Rehmus^{1,12}, Douglas Morrison^{1,13}, Audi
Setiadi^{1,13}, Sara Mostafavi^{5,14}, Michael S. Kobor^{5,7}, Frederick K. Kozak⁸, Catherine M.
Biggs^{1,15}, Clara van Karnebeek^{1,7}, Kyla J. Hildebrand^{1,15}, Anna Lehman on behalf of the
Care4Rare Canada Consortium⁵, Megan K. Levings^{3,4,16}, Stuart E. Turvey^{1,2,14}

- ¹Department of Pediatrics, BC Children's Hospital, The University of British Columbia,
- 11 Vancouver, BC, Canada
- ¹² ²Experimental Medicine Program, Faculty of Medicine, The University of British
- 13 Columbia, Vancouver, BC, Canada
- ³BC Children's Hospital Research Institute, Vancouver, BC, Canada
- ⁴Department of Surgery, The University of British Columbia, Vancouver, BC, Canada
- ⁵Department of Medical Genetics, The University of British Columbia, Vancouver, BC,
 Canada
- ⁶Genome Science and Technology Program, Faculty of Science, The University of British Columbia, Vancouver, BC, Canada
- ⁷Centre for Molecular Medicine and Therapeutics, Vancouver, BC, Canada
- ⁸Division of Otolaryngology Head & Neck Surgery, BC Children's Hospital, The
- 22 University of British Columbia, Vancouver, BC, Canada
- ⁹Division of Hematology, Oncology & Bone Marrow Transplant, BC Children's Hospital,
 The University of British Columbia, Vancouver, BC, Canada
- ¹⁰Division of Respiratory Medicine, BC Children's Hospital, The University of British
- 26 Columbia, Vancouver, BC, Canada
- ¹¹Division of Plastic Surgery, BC Children's Hospital, The University of British Columbia,
 Vancouver, BC, Canada
- ¹²Division of Dermatology, BC Children's Hospital, The University of British Columbia,
 Vancouver, BC, Canada
- ¹³Department of Pathology and Laboratory Medicine, BC Children's Hospital, The
- 32 University of British Columbia, Vancouver, BC, Canada
- ¹⁴Department of Statistics, The University of British Columbia, Vancouver, BC, Canada
- ¹⁵Division of Allergy and Clinical Immunology, BC Children's Hospital, The University of
 British Columbia, Vancouver, BC, Canada
- ¹⁶School of Biomedical Engineering, The University of British Columbia, Vancouver, BC,
- 37 Canada
- 38
- 39
- 40

It is made available under a CC-BY-NC-ND 4.0 International license .

41	Correspondence to:	Stuart E. Turvey, MBBS, DPhil, FRCPC
42		BC Children's Hospital
43		950 West 28 th Avenue
44		Vancouver, BC, V5Z 4H4, Canada
45		Phone: 604 875 2345 ext. 5094
46		Email: <u>sturvey@bcchr.ca</u>

- 47 Word count: 4107
- 48 **Reference count**: 52

It is made available under a CC-BY-NC-ND 4.0 International license .

49 **Abstract:**

Monogenic defects that impair the control of inflammation and tolerance lead to 50 profound immune dysregulation, including autoimmunity and atopy. Studying these 51 52 disorders reveals important molecular and cellular factors that regulate human immune homeostasis and identifies potential precision medicine targets. Here, we provide a 53 detailed immunological assessment of a pediatric patient with a recently discovered 54 55 syndrome causing Immunodysregulation, Craniofacial anomalies, Hearing impairment, 56 Athelia, and Developmental delay (or ICHAD syndrome). The immunodysregulation resulted in autoimmune hemolytic anemia (AIHA) and atopic dermatitis. The patient 57 58 carried de novo germline heterozvaous а 59 c.406+540_574+13477dup;p.Gly136_Ser191dup variant in IKAROS family zinc finger 2 (IKZF2), which encodes Helios. This variant led to reduced Helios protein expression 60 and dominant interference of wild-type Helios-mediated repression of the *IL2* promoter. 61 62 Multi-parameter flow cytometric analyses of patient peripheral blood mononuclear cells revealed strongly impaired natural killer cell differentiation and function, and increased 63 CD8⁺ T cell activation and cytokine secretion. Strikingly, patient CD4⁺ T cells were 64 hyperactive, produced elevated levels of nearly all T helper (T_H) cytokines, and readily 65 proliferated in response to stimulation. Patient regulatory T cells (Tregs) developed 66 normally but aberrantly produced high levels of many T_H cytokines. Single-cell RNA 67 68 sequencing revealed largely normal Tregs (albeit mostly memory), but naïve CD4⁺ T cells that were more enriched in genes related to activation, proliferation, metabolism, 69 and T_H differentiation. This work describes the immunological phenotype of one of the 70 71 first reported cases of germline dominant negative Helios deficiency, expands our 72 understanding of the pathogenesis of AIHA on a single cell level, and provides valuable 73 insights into Helios function in a variety of lymphocyte subsets.

74

It is made available under a CC-BY-NC-ND 4.0 International license .

75 **INTRODUCTION**

76 Immunity is tightly regulated to optimize protective responses against pathogens and 77 malignancy while preventing inappropriate responses to otherwise benign antigens. 78 Monogenic defects that impair this regulation of inflammation or tolerance result in a subgroup of the inborn errors of immunity (IEI) called primary immune regulatory 79 disorders (PIRD)¹. In contrast to classic IEIs, which typically manifest as unusually 80 severe or recurrent infections, PIRDs predominantly present with immune-mediated 81 82 pathology, including autoimmunity, lymphoproliferation, malignancy, autoinflammation, and atopy, with susceptibility to infections being a less pronounced aspect of these 83 disorders². 84

85 Immune dysregulation can lead to a variety of hematologic manifestations and cytopenias³. A classic example is autoimmune hemolytic anemia (AIHA) caused by 86 87 immune-mediated destruction of erythrocytes⁴. AIHA can be idiopathic (primary) or secondary and is classified as warm or cold (cold agglutinin disease [CAD], paroxysmal 88 89 cold hemoglobinuria) depending on autoantibody behaviour at different thermal ranges, which is important for determining appropriate treatment regimens⁵. Most cases of AIHA 90 are considered idiopathic $(\sim 60\%)^6$, while secondary causes can include IEIs/PIRDs, 91 malignancy, bacterial/viral infections, and drugs⁴. As such, the etiology and 92 93 pathogenesis of AIHA remains incompletely understood.

94 In the past 2 years, human germline variants in a family of transcription factors called 95 the IKAROS zinc finger (IKZF) family have been linked to immunodeficiency and cytopenias⁷⁻¹⁰. Notably, loss-of-function (LOF) variants in *IKZF*2 (Helios) were recently 96 97 associated with combined immunodeficiency (CID) and/or immune dysregulation, including immune thrombocytopenia (ITP), Evan's syndrome, and systemic lupus 98 erythematosus⁷⁻⁹. *IKZF2* is highly expressed in hematopoietic stem/progenitor cells, T 99 cells, including activated CD4⁺/CD8⁺ T cells, mucosa-associated invariant T (MAIT) 100 cells, regulatory T cells (Tregs), and natural killer (NK) cells¹¹⁻¹⁶. As Tregs are among 101 the highest IKZF2 expressors, most studies have focused on the role of Helios in Treg. 102 development and function¹⁷⁻²⁷. In mice, Helios is critical for Treg identity, survival, and 103 stability, but is seemingly dispensable in mice and humans for suppressive function^{20,27}. 104

It is made available under a CC-BY-NC-ND 4.0 International license .

Nevertheless, both $IKZF2^{-/-}$ and Treg-specific $IKZF2^{-/-}$ mice develop progressive autoimmune disease associated with activated CD4⁺/CD8⁺ T cells, increased T follicular helper (T_{FH}) and germinal center (GC) B cell numbers, autoantibody production, and increased proinflammatory cytokine production^{19,20,28}. The role of *IKZF2* in other components of the human immune system (e.g. NK cells) is beginning to be better defined through the identification of humans with germline *IKZF2* variants⁷⁻¹⁰.

Here, we report a detailed immunological and mechanistic workup of the first reported 111 case of germline heterozygous dominant negative (DN) *IKZF2* disorder in a young girl 112 we recently described¹⁰. This patient was found to have a novel genetic syndrome 113 comprising Immunodysregulation, Craniofacial anomalies, Hearing impairment, Athelia, 114 115 and Developmental delay (or ICHAD syndrome). We report a comprehensive 116 mechanistic immune evaluation of this patient which revealed significant developmental and functional defects in NK and naïve CD4⁺ T cells and marked immune activation as 117 the likely cause of immune dysregulation. Informed by our improved appreciation of the 118 human phenotype caused by germline IKZF2 variants, we suggest that germline 119 120 heterozygous dominant negative IKZF2 variants should now be considered in the 121 differential diagnosis of patients with AIHA and PIRD.

122

It is made available under a CC-BY-NC-ND 4.0 International license .

123 **METHODS**

124 Study participants and consent

- 125 All study participants and/or their parents/guardians provided written informed consent.
- Research study protocols (H18-02853, H18-02912, H15-00092) were approved by The
- 127 University of British Columbia Clinical Research Ethics Board.

128 Cell isolation, culture, and immortalization

Peripheral blood mononuclear cells (PBMCs) were isolated from all study participants by standard Ficoll-Paque (GE Healthcare) density centrifugation as previously described²⁹. Lymphoblastoid cell lines (LCLs) were derived by standard EBV transformation as previously described²⁹ (**Supplement**).

133 Plasmid generation and cloning

WT *IZKF2*, p.Gly136_Ser191dup *IKZF2*, pIL2-Luc2 plasmids were generated by introducing restriction sites into cDNA or genomic DNA by PCR and cloning into pCMV6-XL4-3xFLAG and p.GL4.14 firefly luciferase gene reporter (Promega) vectors, respectively (**Supplement**).

138 **Transient transfections**

HEK293 cells were transfected with empty vector (EV), WT, p.Gly136_Ser191dup, or varying ratios of WT/p.Gly136_Ser191dup *IKZF2* expression plasmids by Lipofectamine 3000 (ThermoFisher) transfection (**Supplement**). Transfected cells were then processed for immunoblotting or immunofluorescence. For luciferase assays, cells were additionally transfected with pIL2-Luc2 and Renilla luciferase (R-Luc) plasmids then processed with a Dual-Glo Luciferase Assay Kit (#E2920, Promega) (**Supplement**).

145 **Immunoblotting**

Helios protein detection was accomplished in LCLs and transfected HEK293 cells by
 standard immunoblotting as previously described²⁹ (Supplement).

148 Immunofluorescence

12mm coverslips were sterilized, HEK293 cells were seeded on top in 6-well plates,allowed to attach for 24h, then transfected as above. Transfected cells were fixed,

- 151 permeabilized, and stained for Helios, DAPI, and F-actin before mounting and imaging
- 152 on a Leica SP5 II Laser Scanning Confocal Microscope (Leica Microsystems GmbH)
- 153 (Supplement).

154 Immunophenotyping

Immunophenotyping and intracellular cytokine was performed as previously described³⁰.
Briefly, PBMCs were stimulated with PMA and ionomycin (P/I) in the presence of
GolgiStop (#554724, BD Biosciences), stained with antibody panels 1-4 (**Supplemental Table 5**) using the eBioscience Foxp3 Transcription Factor Staining Buffer Set (#005523-00, Invitrogen, ThermoFisher), acquired on a FACSymphony flow cytometer, and
analyzed using FlowJo (both BD Biosciences) (**Supplement**).

161 **Proliferation assays**

PBMCs were seeded at varying concentrations, labelled with Cell Proliferation Dye (CPD) eF450 (#65-0842-85, Invitrogen, ThermoFisher) and stimulated with anti-CD3/CD28-coated Dynabeads (#11141D, Human T-Expander, Gibco, ThermoFisher) for four days. Cells were stained with antibody panel 6 (**Supplemental Table 5**) and acquired on a CytoFLEX (Beckman Coulter) and analyzed using FlowJo (**Supplement**).

167 **T cell suppression assays**

Treg suppression of CD3⁺ T cell proliferation was assessed as previously described²⁷.
Briefly, patient and control PBMCs were enriched for CD4⁺ T cells, sorted using panel 7
(Supplemental Table 5) for Tregs and Tconvs, expanded with IL-2 and irradiated
mouse L cells for seven days, then cocultured with various ratios of CPD-labelled antiCD3/CD28 Dynabead-stimulated enriched CD3⁺ T responder (Tresp) cells for four days.
Percent suppression of CD4⁺ and CD8⁺ T cell proliferation was calculated using division
index (DI): (1 - [DI of sample/DI of positive control]) x 100% (Supplement).

175 Quantification of cytokine production

Supernatants were collected from PBMCs stimulated for proliferation, cocultured Tregs
and Tresp for T cell suppression assays, and stimulated Tregs and Tconvs alone.
Cytokine concentrations were measured by LEGENDplex Human Th Cytokine Panel
12-plex (#741027, BioLegend) on a CytoFLEX (Beckman Coulter) and analyzed with

It is made available under a CC-BY-NC-ND 4.0 International license .

180 Qognit software (BioLegend) according to manufacturer's recommendations181 (Supplement).

182 **TSDR methylation**

Genomic DNA was isolated from expanded Tregs and Tconvs, bisulfite converted with an EZ DNA Methylation-Direct Kit (Zymo Research), PCR amplified, and pyrosequenced using a PyroMark Q96 MD (Qiagen) as previously described²⁷ (**Supplement**).

187 Single-cell RNA sequencing

Single-cell RNA sequencing was performed on unstimulated and 4h P/I-stimulated sorted Tregs and Tconv from P1 and two age-matched/sex-matched controls using the BD Rhapsody Single Cell platform (BD Biosciences) according to manufacturer's recommendations and analyzed as previously described³⁰ (**Supplement**). Raw data are deposited on Gene Expression Omnibus.

193

It is made available under a CC-BY-NC-ND 4.0 International license .

194 **RESULTS**

195 Clinical case presentation

196 The index patient (P1) is a 5-10-year-old girl born to non-consanguineous parents 197 (Figure 1A) who presented with syndromic features of developmental abnormalities and 198 immune dysregulation. Family history is unremarkable. She has profound bilateral sensorineural hearing loss, microcephaly, mild developmental delay, cleft palate, 199 hypotonia, athelia, and dysmorphic facies (detailed in¹⁰). Consistent with underlying 200 201 immune dysregulation, she has suffered from chronic anemia beginning at two months 202 of age, which at times required hospitalization and red blood cell transfusions (Figure 203 **1B-I**). She also had severe atopic dermatitis beginning at ten months of age affecting 204 the face, arms, legs, and trunk. Her skin inflammation was initially refractory to optimal medical therapy (i.e. topical corticosteroids, emollients, bleach baths), but has become 205 206 more manageable with age. The patient also experienced frequent upper respiratory 207 tract infections, which reduced in frequency following initiation of monthly intravenous 208 immunoglobulin (IVIG) replacement therapy. Laboratory and hematologic evaluation 209 revealed chronically positive direct antiglobulin tests (DAT) initially consistent with a 210 mixed (cold>warm) AIHA phenotype, which progressed to a predominantly warm AIHA 211 phenotype with age without overt hemolysis. Other notable hematological features 212 included a normocellular bone marrow with scattered hemophagocytic macrophages, no morphological evidence for dysplastic cells or a progressive marrow disorder, 213 214 lymphopenia, and elevated IgE (Table 1). Red cells did not carry any hemoglobin variants, although non-specific poikilocytosis and rouleaux formation were noted. 215

Given the unique constellation of features, P1 underwent trio WGS (detailed in¹⁰). This 216 217 revealed a novel de novo germline heterozygous structural variant affecting IKAROS zinc finger 2 (IKZF2) encoding Helios (NM_016260.3:c.406+540_574+13477dup; 218 NP_057344.2:p.Gly136_Ser191dup) (Figure 1J-K). The variant results in intron 5 at 219 220 chr2:213900960 being joined to intron 6 chr2:213921017 (GRCh37) with a 2 bp GT insertion in between. This leads to tandem duplication of exon 5 (~20kb duplication 221 222 spanning exon 5 and parts of flanking introns), corresponding to tandem duplication of 223 zinc fingers 2 and 3 of Helios (Figure 1K).

224 Characterization of the impact of the p.Gly136_Ser191dup Helios variant on 225 protein expression and localization

226 The p.Gly136 Ser191dup Helios variant created a higher molecular weight Helios 227 protein (as anticipated with a ~13kDa 56 amino acid duplication) detected in both 228 transfected HEK293 cells and primary patient-derived LCLs (Figure 2A, C and detailed 229 in¹⁰). Total Helios protein expression was reduced overall in both transfected HEK293 230 (Figure 2A-B) and patient-derived LCLs (Figure 2C-E), likely because the variant 231 protein was less stable. As a TF, Helios localizes to the nucleus to regulate transcription¹². We transfected HEK293 cells with WT or p.Gly136 Ser191dup *IKZF2* 232 233 alone, or increasing quantities of p.Gly136_Ser191dup together with WT IKZF2 (Figure 2F) to assess protein expression by immunofluorescence. The variant protein was 234 235 indistinguishable from WT protein in nuclear localization, nor did it affect the nuclear 236 localization of WT protein.

237 p.Gly136_Val192dup Helios acts through dominant interference

238 Helios has previously been shown to bind the *IL2* promoter to silence IL-2 production in Tregs³². We therefore cloned the human *IL2* promoter (-580 bp to +57 bp) into a firefly 239 240 luciferase gene reporter vector and cotransfected this with Renilla luciferase, WT or p.Glv136 Ser191dup IKZF2 alone, or p.Glv136 Ser191dup together with WT (Figure 241 **2G** and detailed in¹⁰). As expected, WT *IKZF2* strongly repressed *IL2* promoter activity. 242 243 However, p.Gly136 Val192dup not only showed impaired repression on its own, but 244 significantly interfered with WT IKZF2-mediated IL2 repression (Figure 2G). This DN 245 effect was dose-dependent, with increasing quantities of p.Gly136_Ser191dup transfected correlating with more impaired WT IKZF2-dependent IL2 repression 246 $(r^2=0.94, p<0.0005)$ (Figure 2H and detailed in¹⁰). 247

Patient lymphocyte phenotyping reveals NK cell lymphocytosis and CD3⁺ T cell lymphopenia

Helios is highly expressed in CD3⁺ T cells and NK cells¹¹, both of which are known to be dysregulated in AIHA⁴. We profiled the frequencies of CD3⁺ T, CD3⁻CD56⁺ NK, and CD3⁺CD56⁺ NKT cells as well as Helios expression from P1 (n=5 independent blood draws) and a cohort of adult (n=8) and age-matched controls (n=11). P1 had

It is made available under a CC-BY-NC-ND 4.0 International license .

significantly reduced frequencies of CD3⁺ T (Figure 3A-B), markedly elevated NK
(Figure 3A,C), and modestly elevated NKT (Figure 3A,D) cells, all of which were
Helios-deficient (Figure 3E-H).

257 P1 NK cells are phenotypically immature and functionally abnormal

Given the intriguing NK cell lymphocytosis, we set out to define the developmental and 258 259 functional status of P1 NK cells by assessing the expression of CD56, maturation (CD27, CD57, CD94), adhesion (CD16), and activation (CD8, CD25) markers³³⁻³⁵ on P1 260 NK cells compared to controls. The relative abundance of CD56^{dim} and CD56^{bright} NK 261 cell populations was normal (Figure 3I-J), although on histograms, the patient lacked a 262 clear CD56^{bright} population (Figure S1A). Strikingly, all maturation markers assessed 263 were dysregulated in P1, including significantly reduced CD16⁺ (Figure 3K, Figure 264 **S1B**) and CD57⁺ (Figure 3L, Figure S1C), but elevated CD27⁺ (Figure 3M, Figure 265 **S1D**) and CD94⁺ (Figure 3N, Figure S1E) NK cells. Similarly, the frequency of CD8⁺ 266 267 NK cells were significantly reduced in the patient both at baseline and in response to stimulation (Figure 30, Figure S1F), while CD25⁺ NK cells (Figure 3P, Figure S1G) 268 269 were normal. This abnormal distribution of markers disproportionately affected CD56^{dim} NK cells more than CD56^{bright} NK cells, although Helios was reduced in both populations 270 (Figure S1H-N). Taken together, patient NK cells are skewed towards an immature 271 272 phenotype.

273 As NK cells mediate their effector functions through the release of proinflammatory cytokines and cytolysis³³, we studied whether these roles were affected in P1. In 274 response to stimulation, P1 had significantly elevated IFN- γ^+ NK cells (Figure 3Q, 275 **Figure S1O**), but comparable TNF- α^+ NK cells (**Figure 3R**, **Figure S1P**). Similarly, P1 276 NK cells expressed significantly less granzyme B (Figure 3S) and perform (Figure 3T), 277 with this effect being more pronounced in CD56^{dim} NK cells (Figure S1Q-R). These 278 defects were confirmed in multidimensional space when we clustered live CD3⁻CD56⁺ 279 280 NK cells from P1 and adult and pediatric controls on CD16, CD27, CD57, CD94, Helios, 281 perforin, granzyme B, IFN- γ , and TNF- α at baseline and in response to stimulation (Figure 3U-V, Figure S1S). 282

It is made available under a CC-BY-NC-ND 4.0 International license .

Patient CD8⁺ T cells are significantly reduced, have high PD-1 expression, and are potent proinflammatory cytokine producers

As CD8⁺ T cells are frequently enriched in autoimmune disease³⁶ and can be clonally expanded in AIHA³⁷, we assessed the frequency of CD8⁺ T cells and subsets and their Helios expression. P1 had profound CD8⁺ T cell lymphopenia (**Figure 4A-B**), significantly elevated frequencies of central memory (CM) with a concurrent reduction in naïve subsets, while effector memory (EM) and TEMRA subsets were normal (**Figure 4C-G**). Importantly, all P1 CD8⁺ T cell subsets were Helios-deficient (**Figure 4H-I**).

PD-1 is a critical inhibitory receptor that is upregulated in activated, memory, or 291 exhausted T cells to restrain effector functions³⁸. We therefore assessed PD-1 292 expression and proinflammatory cytokine production in P1 CD8⁺ T cells. In line with 293 294 elevated CD8 CM, we discovered significantly more PD-1 expression on P1 CD8⁺ T cells (Figure 4J-K). These T cells are likely not exhausted as both naïve and total 295 296 memory CD8⁺ T cells produced significantly more TNF- α (Figure 4L-N) and IFN- γ (Figure 40-Q) than controls, while CD8⁺ T cell proliferation was comparable to controls 297 298 (Figure 4R-S).

P1 CD19⁺ B cells show largely normal development but increased TNF-α production

Although Ikaros and Aiolos are both critical for B cell differentiation³⁹, the role of Helios 301 302 in these cells is less clear. Helios silencing is thought to maintain B cell function as ectopic expression leads to B cell hyperresponsiveness and lymphomagenesis⁴⁰. We 303 304 therefore studied the development and function of P1 B cells. In general, B cell 305 development was largely normal, with intact total CD19⁺ (Figure S2A-B), naïve (Figure 306 S2C, D), switched memory [SM] (Figure S2C, F), and plasmablasts (Figure S2I-J). 307 However, we did observe significantly increased non-switched memory [NSM] (Figure 308 S2C, E) and decreased transitional B cells (Figure S2G-H), while Helios was lowly 309 expressed in all B cell populations from both P1 and controls (Figure S2K-L). In response to stimulation, patient B cells produced significantly more TNF- α than controls 310 311 (Figure S2M). This applied to NSM (Figure S2N), SM (Figure S2O), and naïve (Figure S2P) subsets. 312

It is made available under a CC-BY-NC-ND 4.0 International license .

313 P1 CD4⁺ T cells are more mature

314 CD4⁺ T helper (T_H) cells and their subsets are critical for both protective antimicrobial immunity and driving pathological states such as autoimmunity and atopic disease⁴¹. 315 We therefore enumerated the frequency of total CD4⁺ T cells and subsets and Helios 316 317 expression. P1 CD4⁺ T cells were modestly elevated (Figure 5A) in line with CD8⁺ T 318 lymphopenia. We also found similar subset distributions to P1 CD8⁺ T cells, including 319 significantly increased CD4⁺ CM (Figure 5B, D), with an associated reduction in naïve (Figure 5B, C), while EM and TEMRA subsets (Figure 5E-F) were normal. Helios 320 expression was low in all CD4⁺ subsets (Figure 5G-H). 321

322 P1 CD4⁺ T cells are hyperresponsive and exhibit effector phenotypes

323 In mice, Treg-specific, but not complete knockout, of *lkzf2* in mice leads to increased PD-1 expression on CD4⁺ T cells²⁰. Surprisingly, P1 had three-fold higher PD-1⁺ CD4⁺ T 324 325 cells than controls (Figure 5I-J), which could signify higher activation status. We thus measured the frequency of T_H subsets and cytokine production. Mirroring our IL2 326 327 promoter luciferase data (Figure 2F-G), we observed a striking increase in IL-2⁺ CD4⁺ T 328 cells in P1 (Figure 5K-L). This was not limited to IL-2, as the patient also had 329 significantly increased IFN- γ^+ and TNF- α^+ CD4⁺ T cells (**Figure 5M-P**) and most T_H 330 subsets, including T_H1 , T_H2 (Figure 5Q-S), T_H9 , T_{FH} (Figure 5T-V), and T_H17 (Figure S3A-B). This also held true when we measured T_H cytokines in the supernatant of 331 332 stimulated PBMCs, where we found markedly elevated concentrations of IL-2, IL-4, IL-5, IL-6, IL-9, IL-13, and TNF- α , even in response to lower bead:cell ratios (Figure 5W, 333 Figure S3C-N). Surprisingly, we observed marked impairment in secreted IL-22 levels 334 335 (Figure S3L). In keeping with this picture of hyperactive CD4⁺ T cells, P1 CD4⁺ T cells more readily proliferated in response to stimulation than controls (97.1% divided in 336 337 patient vs. 54.5% in control) (Figure 5X-Y).

338 P1 has normal Treg frequencies and TSDR methylation

~70-80% of Tregs express Helios and at least in mice, this is thought to be important for
 regulating Treg identity and function⁴². As Tregs are critical mediators of
 tolerance/homeostasis and their dysfunction is associated with allergic and autoimmune
 disease⁴³, we enumerated their frequency and Helios expression in P1. P1 had normal

It is made available under a CC-BY-NC-ND 4.0 International license .

frequencies of CD3⁺CD4⁺CD8⁻CD25⁺CD127^{lo}FOXP3⁺ Tregs (Figure 6A, Figure S4A),
but significantly reduced Helios expression (Figure 6B-C).

Since methylation of the Treg-specific demethylated region (TSDR) in the *FOXP3* gene is important for maintaining stable FOXP3 expression and Treg suppressive function^{44,45}, we quantified expanded P1 Treg TSDR methylation and FOXP3 expression in comparison to Tregs from healthy female controls. TSDR methylation was normal (**Figure 6D**), although the average methylation trended to higher in P1 (**Figure S4B**). Ex vivo P1 Tregs had significantly higher FOXP3 expression than controls, likely reflecting a higher state of activation (**Figure 6E**).

352 P1 Tregs are predominantly PD-1⁺ and are potent T_H cytokine producers

Given the striking increase in PD-1⁺ CD4+ (Figure 5I-J) and CD8⁺ (Figure 4J-K) T cells 353 354 in P1, we assessed PD-1 expression in P1 ex vivo Tregs. Similarly, P1 had significantly 355 more PD-1⁺ Tregs (~80%) than controls (~40%) (Figure 6F, Figure S4C). Helios genetic or pharmacological targeting in Tregs leads to elevated IL- 2^{32} , IFN- γ , and IL-356 $17A^{19,20,28,46}$ and effector T_H cell signatures⁴⁷. We thus studied T_H cytokine production in 357 358 ex vivo Treqs and discovered significantly elevated IL-2⁺ Treqs in P1 (Figure 6G-H), confirming our *IL2* luciferase data (Figure 2F-G). P1 also had a striking increase in IL-4⁺ 359 360 (Figure 6I-J), IFN- γ^+ (Figure 6I, K), IL-9⁺ (Figure 6L, Figure S4D), IL-21⁺ (Figure 6M, 361 **Figure S4D**), and TNF- α^+ (**Figure 6N-O**) Treqs. Expanded P1 Treqs also produced 362 higher concentrations of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, and IL-17F (Figure 6P, 363 Figure S4C-N).

P1 Tregs have impaired suppressive function are not intrinsically resistant to being suppressed

The abnormal cytokine production in P1 Tregs prompted us to investigate their ability to suppress T responder (Tresp) proliferation and cytokine production. We cocultured expanded P1 and control Tregs at different ratios with stimulated control CD3⁺ Tresp. We discovered no significant differences between patient or control Treg-mediated suppression of CD4⁺ (**Figure 6Q**) or CD8⁺ (**Figure 6R**) T cell proliferation, although suppression trended to lower in the 1:2.5 and 1:5 Treg:CD3 T cell ratios.

It is made available under a CC-BY-NC-ND 4.0 International license .

An intrinsic resistance to Treg-mediated suppression could also contribute to the patient's prominent hyperactivation phenotype. We reversed our setup from above and cocultured control Tregs with P1 CD3⁺ Tresp and measured suppression of T_H cytokines. P1 T_H cytokine production was effectively suppressed by control Tregs (**Figure 6S, Figure S5**), excluding an intrinsic defect in susceptibility to suppression.

377 scRNA-seq reveals a predominantly memory and effector phenotype in P1 Tregs

378 To assess transcriptomic pathways that could drive the striking patient Treg phenotype. we sorted CD4⁺CD25⁺CD127^{lo} Tregs from P1 and two age-matched/sex-matched 379 controls (Figure S6A). We carried out whole transcriptome single-cell RNA sequencing 380 381 (scRNA-seq) on Tregs from P1 (n=295 cells) and controls (n=331 cells) and performed 382 dimensionality reduction using the uniform manifold approximation and projection (UMAP) method⁴⁸. Patient Treas clustered separately from controls (Figure 7A) and 383 when cell identity was annotated using the DICE project⁴⁹, they were predominantly 384 385 labelled as memory Treg and T_H subsets (T_H1 T_H2, T_H17, T_{FH}), in line with the activated and aberrant cytokine phenotype observed (Figure 6F-P). Similarly, annotation based 386 387 on CD45RA AbSeq/HLA-DR AbSeq expression to identify CD45RA⁺HLA-DR⁻ naïve, CD45RA⁻HLA-DR⁺ activated, and CD45RA⁻HLA-DR⁻ Tregs^{50,51} also found that P1 Tregs 388 predominantly CD45RA⁻HLA-DR⁺ 389 and CD45RA⁻HLA-DR⁻. (Figure 7B). were 390 Nevertheless, P1 Treg subsets were transcriptomically similar to control Tregs (Figure 391 7C-E, Figure S6B-D), except for significantly increased IL2, PDCD1, and CCR4 392 transcript abundance in P1 naïve Treqs (Figure 7C), consistent with our flow cytometry 393 data (Figure 6F-H).

394 scRNA-seq reveals a predominantly memory and effector phenotype in P1 CD4⁺ 395 Tconvs

Given the profound CD4 phenotype, we also sorted CD4⁺CD25⁻CD127⁺ Tconv cells from P1 and two age-matched/sex-matched controls and performed scRNA-seq (P1 n=854 cells; control n=1225 cells) (**Figure S7A**). Like Tregs, P1 Tconv clustered separately from controls and were frequently labelled as T_H subsets (**Figure 7F**) and CD45RA⁻ memory (**Figure 7G**). When comparing the transcriptome of AbSeq-inferred naïve (**Figure 7H, Figure S7E**) and memory (**Figure 7I, Figure S7F**) CD4⁺ Tconv cells

It is made available under a CC-BY-NC-ND 4.0 International license .

between P1 and controls, we found similar memory, but distinctly different naïve
populations. Unstimulated naïve P1 CD4⁺ Tconv cells had significantly higher transcript
abundance of genes related to IL-2 signalling, activation, and migration (*IL2RB, CXCR4, PDCD1, CCL5, JUN*). Stimulated P1 CD4⁺ Tconv cells had significantly higher
expression of proinflammatory cytokine/chemokine genes (*IL2, IFNG, TNF, CCL4*),
confirming our CD4⁺ phenotyping data (Figure 5K-P).

408 **P1 CD4⁺ Tconvs are poised for T_H differentiation**

To study what pathways could be driving naïve CD4⁺ Tconv differences, we carried out 409 gene set enrichment analyses. Unstimulated naïve P1 CD4⁺ Tconv cells were more 410 enriched in pathways related to proliferation, IL-6 signalling, allograft rejection, 411 apoptosis, and hypoxia. Further, stimulated patient CD4⁺ Tconv cells showed significant 412 413 enrichment in proliferation (Myc targets V1/V2), metabolism (glycolysis, gluconeogenesis, mTORC1 signaling), Treg survival (IL-2-STAT5), impaired tolerance 414 415 (allograft rejection), atopy (TSLP pathway), and T_{H} differentiation (IL-27-/IL-12-/IL-23mediated signalling events, T_H1 , T_H2 , T_H17 cell differentiation) pathways (**Figure 7J**). In 416 417 line with the primed/poised phenotype of P1 naïve CD4⁺ Tconv cells, we observed 418 significantly increased IL-2⁺ (Figure 7K-L), IFN- γ^+ (Figure 7M-N), and TNF- α^+ (Figure **70-P**) naïve P1 CD4⁺ T cells, with a similar trend observed in memory. 419

420

It is made available under a CC-BY-NC-ND 4.0 International license .

421 **DISCUSSION**

422 Germline pathogenic variants in *IKZF2* have only been discovered in humans in the past two years. The initial descriptions were of germline heterozygous or homozygous 423 LOF *IKZF2* variants in a total of 13 patients with combined immunodeficiency and/or 424 immune dysregulation⁷⁻⁹ (summarized in Figure S7A, Table S3). Collectively, these 425 426 germline LOF IKZF2 variants were predominantly heterozygous (10/13) and were mostly associated with evidence of immune dysregulation (10/13) (Table S4), including 427 systemic lupus erythematosus (SLE), hemophagocytic lymphohistiocytosis (HLH), 428 429 idiopathic thrombocytopenic purpura (ITP), and Evan's syndrome. Our group recently expanded this list through the discovery of 2 patients with germline DN IKZF2 variants 430 who presented with ICHAD syndrome¹⁰. Notably the patient carrying the DN pathogenic 431 c.406+540 574+13477dup;p.Gly136 Ser191dup *IKZF*2 variant 432 (designated P1) 433 experienced the most severe clinical manifestations of immune dysregulation out of all 15 patients described to date with pathogenic germline *IKZF2* variants (Figure S7B). P1 434 presented with syndromic developmental features plus significant chronic AIHA and 435 436 atopic dermatitis, features consistent with classification as a PIRD. Given the profound 437 immune dysregulation associated with the DN pathogenic c.406+540 574+13477dup;p.Gly136 Ser191dup IKZF2 variant, we embarked on a 438 439 detailed immunological assessment of P1.

440 Immunophenotyping of this patient with DN IKZF2 deficiency revealed striking differences from previous homozygous and heterozygous LOF patients and mice. For 441 example, P1 NK cells were phenotypically immature and likely hyperactive due to 442 elevated IFN-y production and reduced intracellular perforin and granzyme B expression 443 (**Figure 3**). In contrast, other reported patients had NK cell lymphopenia^{8,9} or normal NK 444 development⁷. Furthermore, while $IKZF2^{-1}$ mice have normal NK cell frequencies²¹, NK 445 446 cells from NKp46-mutant mice (Noé) show elevated Helios expression and effector 447 function, which modulates protective memory CD4⁺/CD8⁺ T cell development⁵². The 448 study of P1 has thus revealed a previously unappreciated role for Helios in human NK 449 cell development and function and calls for more in-depth studies in the future.

Helios has been extensively studied in mouse Tregs⁴², but its role in human Tregs has 450 451 remained relatively unclear. Previous CRISPR-mediated KO studies by our co-authors 452 found that Helios is dispensable for lineage stability and suppressive function in fully differentiated Tregs²⁷, whereas germline homozygous or heterozygous LOF *IKZF2* 453 454 variants caused a proinflammatory Treg phenotype associated with increased IL-2 and IFN- γ production, but intact suppressive function^{7,8}. Our functional studies with this DN 455 IKZF2 variant confirm that it is not required for Treg development, but that it is essential 456 457 for inhibition of IL-2 expression and many other cytokines. Although functional suppression of T cell proliferation appeared normal, aberrant production of many T_H 458 cytokines likely contributes to a functional defect in immune regulation in vivo (Figure 459 6), which is exacerbated by the greater propensity of P1 naïve CD4⁺ T cells to 460 461 differentiate into effector CD4⁺ T cell subsets (T_H1 , T_H2 , T_H9 , T_{FH}).

Taken together, we have defined the immune phenotype of a novel form of Helios deficiency caused by a DN variant, which leads to severe congenital AIHA and atopic dermatitis¹⁰. This study identifies new players in the pathogenesis of these immunemediated disorders and has significantly expanded our understanding of human Helios, including its regulation of naïve CD4 T cell differentiation into memory/effector subsets and NK cell development and function.

468

It is made available under a CC-BY-NC-ND 4.0 International license .

469 **ACKNOWLEDGEMENTS**

470 This work was supported in part by grants from the Canadian Institutes of Health Research (PJT 178054 to S.E.T.; FDN-154304 to M.K.L.), Genome British Columbia 471 (SIP007) (S.E.T.), and BC Children's Hospital Foundation. S.E.T. holds a Tier 1 Canada 472 Research Chair in Pediatric Precision Health and the Aubrey J. Tingle Professor of 473 474 Pediatric Immunology. M.K.L. receives a BCCHR salary award and holds a Tier 1 Canada Research Chair in Engineered Immune Tolerance. H.Y.L. is supported by a 475 476 CIHR Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral 477 Award (CGS-D), University of British Columbia Four Year Doctoral Fellowship (4YF), Killam Doctoral Scholarship, Friedman Award for Scholars in Health, and a BC 478 479 Children's Hospital Research Institute Graduate Studentship. M.V.S. is supported by a 480 Vanier Canada Graduate Scholarship and 4YF. A.J.L. is supported by a CGS-D and 481 4YF. M.S. is supported by a CGS-D and 4YF. We would like to acknowledge the Flow Cytometry and Imaging cores at BC Children's Hospital Research Institute for providing 482 the equipment for microscopy, flow cytometry, and cell sorting, the Biomedical 483 484 Research Centre Sequencing Core (BRC-Seq) for their assistance with single-cell RNA 485 sequencing and data processing, The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Canada for their assistance with whole genome sequencing, 486 487 and the BC Children's Hospital BioBank for providing access to age-matched and sexmatched control peripheral blood mononuclear cells. 488

489 AUTHORSHIP CONTRIBUTIONS

H.Y.L, A.L., and S.E.T. were responsible for study conception and design. H.Y.L., 490 491 M.V.S., A.J.L., M.S., J.G., G.X.Y., S.L. performed experiments. A.M., C.V., A.L., S.M. conducted genetic screening and variant prioritization. H.Y.L., M.S., M.P.F., M.S.K., A.M. 492 493 performed bioinformatics analyses or provided computational resources. H.Y.L., M.V.S., A.S., R.R., L.A., J.H., C.L.Y., M.C., E.H., Au.S., F.K.K., K.J.H., C.M.B., C.V., A.L., 494 495 S.E.T. collected and analyzed clinical data. H.Y.L., M.V.S., A.J.L., M.S., A.M., J.G., G.X.Y., M.K.L., S.E.T. analyzed and interpreted data. H.Y.L. and S.E.T. wrote the 496 497 manuscript with input from all authors. All authors read and approved the final version of the manuscript. 498

It is made available under a CC-BY-NC-ND 4.0 International license .

499 DISCLOSURE OF CONFLICTS OF INTEREST

500 The authors declare no competing financial interests.

501

502

It is made available under a CC-BY-NC-ND 4.0 International license .

503 **REFERENCES**

504

 Chan AY, Torgerson TR. Primary immune regulatory disorders: a growing universe of immune dysregulation. *Curr Opin Allergy Clin Immunol*. 2020;20(6):582-590.
 Flinn AM, Gennery AR. Primary immune regulatory disorders: Undiagnosed needles in the haystack? *Orphanet J Rare Dis*. 2022;17(1):99.

509 3. Seidel MG. Autoimmune and other cytopenias in primary immunodeficiencies: 510 pathomechanisms, novel differential diagnoses, and treatment. *Blood*. 511 2014;124(15):2337-2344.

- 512 4. Michalak SS, Olewicz-Gawlik A, Rupa-Matysek J, Wolny-Rokicka E, 513 Nowakowska E, Gil L. Autoimmune hemolytic anemia: current knowledge and 514 perspectives. *Immun Ageing*. 2020;17(1):38.
- 515 5. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. 516 *Haematologica*. 2014;99(10):1547-1554.
- 517 6. Tranekaer S, Hansen DL, Frederiksen H. Epidemiology of Secondary Warm 518 Autoimmune Haemolytic Anaemia-A Systematic Review and Meta-Analysis. *J Clin Med.* 519 2021;10(6).
- 520 7. Hetemaki I, Kaustio M, Kinnunen M, et al. Loss-of-function mutation in IKZF2 521 leads to immunodeficiency with dysregulated germinal center reactions and reduction of 522 MAIT cells. *Sci Immunol.* 2021;6(65):eabe3454.
- 523 8. Shahin T, Kuehn HS, Shoeb MR, et al. Germline biallelic mutation affecting the 524 transcription factor Helios causes pleiotropic defects of immunity. *Sci Immunol.* 525 2021;6(65):eabe3981.
- 526 9. Shahin T, Mayr D, Shoeb MR, et al. Identification of germline monoallelic 527 mutations in IKZF2 in patients with immune dysregulation. *Blood Adv.* 2022;6(7):2444-528 2451.
- 529 10. Mohajeri A, Vaseghi-Shanjani M, Rosenfeld JA, et al. Dominant negative variants 530 cause syndrome. new disorder characterised in IKZF2 ICHAD а bv 531 immunodysregulation, craniofacial anomalies, hearing impairment, athelia and developmental delay. J Med Genet. 2023. 532
- 533 11. Kelley CM, Ikeda T, Koipally J, et al. Helios, a novel dimerization partner of 534 Ikaros expressed in the earliest hematopoietic progenitors. *Curr Biol.* 1998;8(9):508-535 515.
- Hahm K, Cobb BS, McCarty AS, et al. Helios, a T cell-restricted lkaros family
 member that quantitatively associates with lkaros at centromeric heterochromatin. *Genes Dev.* 1998;12(6):782-796.
- 539 13. Getnet D, Grosso JF, Goldberg MV, et al. A role for the transcription factor Helios
 540 in human CD4(+)CD25(+) regulatory T cells. *Mol Immunol.* 2010;47(7-8):1595-1600.
- 541 14. Akimova T, Beier UH, Wang L, Levine MH, Hancock WW. Helios expression is a 542 marker of T cell activation and proliferation. *PLoS One*. 2011;6(8):e24226.
- 543 15. Serre K, Benezech C, Desanti G, et al. Helios is associated with CD4 T cells
 544 differentiating to T helper 2 and follicular helper T cells in vivo independently of Foxp3
 545 expression. *PLoS One*. 2011;6(6):e20731.
- Leeansyah E, Svard J, Dias J, et al. Arming of MAIT Cell Cytolytic Antimicrobial
 Activity Is Induced by IL-7 and Defective in HIV-1 Infection. *PLoS Pathog.*2015;11(8):e1005072.

549 17. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros 550 transcription factor family member, differentiates thymic-derived from peripherally 551 induced Foxp3+ T regulatory cells. *J Immunol*. 2010;184(7):3433-3441.

Thornton AM, Lu J, Korty PE, et al. Helios(+) and Helios(-) Treg subpopulations
 are phenotypically and functionally distinct and express dissimilar TCR repertoires. *Eur J Immunol.* 2019;49(3):398-412.

555 19. Kim HJ, Barnitz RA, Kreslavsky T, et al. Stable inhibitory activity of regulatory T 556 cells requires the transcription factor Helios. *Science*. 2015;350(6258):334-339.

557 20. Sebastian M, Lopez-Ocasio M, Metidji A, Rieder SA, Shevach EM, Thornton AM. 558 Helios Controls a Limited Subset of Regulatory T Cell Functions. *J Immunol.* 559 2016;196(1):144-155.

560 21. Cai Q, Dierich A, Oulad-Abdelghani M, Chan S, Kastner P. Helios deficiency has 561 minimal impact on T cell development and function. *J Immunol*. 2009;183(4):2303-2311.

562 22. Ross EM, Bourges D, Hogan TV, Gleeson PA, van Driel IR. Helios defines T 563 cells being driven to tolerance in the periphery and thymus. *Eur J Immunol.* 564 2014;44(7):2048-2058.

Skadow M, Penna VR, Galant-Swafford J, Shevach EM, Thornton AM. Helios
Deficiency Predisposes the Differentiation of CD4(+)Foxp3(-) T Cells into Peripherally
Derived Regulatory T Cells. *J Immunol.* 2019;203(2):370-378.

568 24. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK. Helios+ and 569 Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. *J* 570 *Immunol*. 2013;190(5):2001-2008.

571 25. Gottschalk RA, Corse E, Allison JP. Expression of Helios in peripherally induced 572 Foxp3+ regulatory T cells. *J Immunol*. 2012;188(3):976-980.

573 26. Ng MSF, Roth TL, Mendoza VF, Marson A, Burt TD. Helios enhances the 574 preferential differentiation of human fetal CD4(+) naive T cells into regulatory T cells. *Sci* 575 *Immunol.* 2019;4(41).

576 27. Lam AJ, Uday P, Gillies JK, Levings MK. Helios is a marker, not a driver, of 577 human Treg stability. *Eur J Immunol*. 2022;52(1):75-84.

578 28. Nakagawa H, Sido JM, Reyes EE, Kiers V, Cantor H, Kim HJ. Instability of 579 Helios-deficient Tregs is associated with conversion to a T-effector phenotype and 580 enhanced antitumor immunity. *Proc Natl Acad Sci U S A*. 2016;113(22):6248-6253.

Lu HY, Sharma M, Sharma AA, et al. Mechanistic understanding of the combined
immunodeficiency in complete human CARD11 deficiency. *J Allergy Clin Immunol.*2021;148(6):1559-1574 e1513.

30. Sharma M, Fu MP, Lu HY, et al. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B cell malignancy. *Blood.* 2022.

586 31. Chessum L, Matern MS, Kelly MC, et al. Helios is a key transcriptional regulator 587 of outer hair cell maturation. *Nature*. 2018;563(7733):696-700.

588 32. Baine I, Basu S, Ames R, Sellers RS, Macian F. Helios induces epigenetic 589 silencing of IL2 gene expression in regulatory T cells. *J Immunol.* 2013;190(3):1008-590 1016.

33. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development,
Maturation, and Clinical Utilization. *Front Immunol.* 2018;9:1869.

593 34. Burk CM, Coffey KE, Mace EM, et al. Immunodeficiency, centromeric instability,

and facial anomalies (ICF) syndrome with NK dysfunction and EBV-driven malignancy

treated with stem cell transplantation. *J Allergy Clin Immunol Pract.* 2020;8(3):1103-1106 e1103.

597 35. Ruiz-Garcia R, Vargas-Hernandez A, Chinn IK, et al. Mutations in PI3K110delta 598 cause impaired natural killer cell function partially rescued by rapamycin treatment. *J* 599 *Allergy Clin Immunol.* 2018;142(2):605-617 e607.

- 600 36. Petrelli A, Mijnheer G, Hoytema van Konijnenburg DP, et al. PD-1+CD8+ T cells 601 are clonally expanding effectors in human chronic inflammation. *J Clin Invest*. 602 2018;128(10):4669-4681.
- 603 37. Smirnova SJ, Sidorova JV, Tsvetaeva NV, et al. Expansion of CD8+ cells in autoimmune hemolytic anemia. *Autoimmunity*. 2016;49(3):147-154.
- 605 38. Kuchroo JR, Hafler DA, Sharpe AH, Lucca LE. The double-edged sword: 606 Harnessing PD-1 blockade in tumor and autoimmunity. *Sci Immunol.* 607 2021;6(65):eabf4034.
- 608 39. Heizmann B, Kastner P, Chan S. The Ikaros family in lymphocyte development. 609 *Curr Opin Immunol.* 2018;51:14-23.
- 40. Dovat S, Montecino-Rodriguez E, Schuman V, Teitell MA, Dorshkind K, Smale ST. Transgenic expression of Helios in B lineage cells alters B cell properties and promotes lymphomagenesis. *J Immunol*. 2005;175(6):3508-3515.
- 41. Zhu X, Zhu J. CD4 T Helper Cell Subsets and Related Human Immunological
 Disorders. *Int J Mol Sci.* 2020;21(21).
- 615 42. Thornton AM, Shevach EM. Helios: still behind the clouds. *Immunology*. 616 2019;158(3):161-170.
- 43. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory
 T Cells and Human Disease. *Annu Rev Immunol.* 2020;38:541-566.
- 619 44. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in 620 regulatory T cells. *PLoS Biol.* 2007;5(2):e38.
- 45. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3 gene expression. *Eur J Immunol*. 2008;38(6):1654-1663.
- 46. Wang ES, Verano AL, Nowak RP, et al. Acute pharmacological degradation of Helios destabilizes regulatory T cells. *Nat Chem Biol.* 2021;17(6):711-717.
- 47. Yates K, Bi K, Haining WN, Cantor H, Kim HJ. Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells. *Proc Natl Acad Sci U S A*. 2018;115(9):2162-2167.
- 48. McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction; 2018:arXiv:1802.03426.
- 49. Schmiedel BJ, Singh D, Madrigal A, et al. Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression. *Cell*. 2018;175(6):1701-1715 e1716.
- 50. Dong S, Maiella S, Xhaard A, et al. Multiparameter single-cell profiling of human CD4+FOXP3+ regulatory T-cell populations in homeostatic conditions and during graftversus-host disease. *Blood*. 2013;122(10):1802-1812.
- 635 51. Rosenblum MD, Way SS, Abbas AK. Regulatory T cell memory. *Nat Rev* 636 *Immunol.* 2016;16(2):90-101.
- Narni-Mancinelli E, Jaeger BN, Bernat C, et al. Tuning of natural killer cell 637 52. 638 Helios calibrates reactivity by NKp46 and Т cell responses. Science. 639 2012;335(6066):344-348.
- 640

It is made available under a CC-BY-NC-ND 4.0 International license .

641

642 **TABLE LEGENDS**

Table 1. Summary of major hematological and immunological laboratory parameters. Tabulation of patient hematological and immunological laboratory values compared to age-specific reference ranges. [‡]value measured while patient was on intravenous immunoglobulin replacement. TREC, T cell receptor excision circle; DAT, direct antiglobulin test; HGB, hemoglobin.

648 **FIGURE LEGENDS**

649 Figure 1. Clinical phenotype of the patient. A) Family pedigree of the patient. Filled symbols indicate affected individuals. Arrow represents index patient. Known genotype 650 651 is marked. B-I) Hematological parameters measured in the patient over time. Shaded 652 regions=age-specific reference ranges. J) Sanger sequencing of DNA extracted from 653 whole blood of the patient. Primers were designed to flank the breakpoint. K) Schematic 654 representation of the impact of i) the c.406+540_574+13477dup IKZF2 variant on the 655 genomic level. Red inset=exon 5 duplication. Blue inset=Sanger sequencing primer 656 location; and ii) the p.Gly136_Ser191dup Helios variant on the protein level. Red 657 inset=zinc finger 2 and 3 duplication. Var., variant; WT, wild-type; ZF, zinc finger; P1, 658 patient 1.

659 Figure 2. A novel *IKZF2* variant leads to reduced Helios protein expression and 660 dominant interference of WT function. A-B) HEK293 cells were transfected with empty vector (EV), wild-type (WT) IKZF2, or p.Gly136_Ser191dup (variant) IKZF2 alone 661 662 or in different combinations. Expression was determined by immunoblotting with both 663 FLAG and Helios. n=5. C-E) Expression of Helios was detected in patient-derived and control lymphoblastoid cell lines (LCLs) and compared to negative (THP-1 monocytic 664 665 cells) and positive (Jurkat T leukemia cells) controls by C-D) immunoblot and E) flow 666 cytometry. F) HEK293 cells were transfected with EV, WT, variant, or ratios of 667 WT:variant and subjected to immunofluorescence for detection of Helios (red, Alexa 668 Fluor 647), the nucleus (blue, DAPI), and F-actin (green, Phalloidin Alexa Fluor 488) 669 using a Leica SP5 Confocal and LAS X Software with a 100x objective lens. Scale

It is made available under a CC-BY-NC-ND 4.0 International license .

bars=5μm. n=3. G-H) HEK293 cells were cotransfected with EV, *IKZF2* expression
plasmids at various ratios, plL2-luc2, and Renilla luciferase. *IL2* promoter activity was
defined as relative light units from different conditions normalized to EV. H) Pearson
correlation between *IL2* promoter activity and % variant/WT *IKZF2* plasmid transfected.
Shaded region=95% confidence interval. n=3. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test.

Figure 3. P1 has impaired NK cell development and function. A) Representative 676 flow cytometry dot plots showing CD3⁺CD56⁻ T cells, CD3⁻CD56⁺ NK cells, and 677 CD3⁺CD56⁺ NKT cells for P1 and a control. B-D) Frequency of B) T cells, C) NK cells, 678 D) NKT cells from A) in P1 and adult (HC^A) and pediatric (HC^P) controls. E) 679 680 Representative Helios histograms for T, NK, and NKT cells in P1 and controls compared to a fluorescence minus one (FMO) control. Mean fluorescence intensities 681 (MFI) are indicated. F-H) Quantification of Helios MFI in F) T cells, G) NK cells, H) NKT 682 cells from P1 and controls. I-N) Frequency of I) CD56^{dim}, J) CD56^{bright} NK, K) CD16⁺, L) 683 CD57⁺, M) CD27⁺, N) CD94⁺ NK cells in P1 compared to controls. O-P) Frequency of N) 684 CD8⁺ and P) CD25⁺ NK cells in patient and controls before and after 4h PMA and 685 ionomycin (P/I) stimulation. Q-R) Frequency of Q) IFN- γ^+ and R) TNF- α^+ NK cells in P1 686 687 and controls after P/I stimulation. S-T) MFI of S) granzyme B and T) perforin in 688 unstimulated P1 and control NK cells. U-V) Live NK cells from P1 or controls clustered on CD16, CD27, CD57, CD94, Helios, perforin, granzyme B, IFN-γ, and TNF-α. Number 689 690 of NK cells clustered for each group is indicated on the panels to the right. V) tSNE plots from U) coloured based on CD16, CD27, CD56, CD57, or CD94 expression. A-N, Q-T) 691 P1 n=5, HC^A n=8, HC^P n=11. O-P) P1 n=3, HC n=8. *p<0.05, **p<0.01, ***p<0.001, 692 ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple comparisons test. 693

Figure 4. P1 CD8⁺ T cells are more differentiated and have enhanced cytokine
production. A) Representative dot plots showing CD3⁺CD4⁻CD8⁺ and CD3⁺CD4⁺CD8⁻
T cells. B) Frequency of CD8⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P) controls.
C) Representative contour plot of naïve (N), central memory (CM), effector memory
(EM), and TEMRA CD8⁺ T cells in the patient and a control. Quadrants corresponding
to each subset are shown to the right. D-G) Quantification of D) naïve, E) CM, F) EM, G)

It is made available under a CC-BY-NC-ND 4.0 International license .

TEMRA CD8⁺ T cells from C). H) Representative Helios histograms for CD8⁺ T cells 700 701 from P1 and three controls compared to a fluorescence minus one (FMO) control. Mean 702 fluorescence intensities (MFI) are indicated. I) Quantification of Helios MFI in different 703 CD8⁺ T cell subsets. J) Representative contour plots for PD-1⁺ CD8⁺ T cells in P1 and a 704 control. K) Quantification of J). L-Q) PBMCs stimulated 4h with PMA+ionomycin. L), O) Representative contour plots for L) TNF- α^+ and O) IFN- γ^+ CD8⁺ T cells in P1 and a 705 control. M-N) Quantification of TNF- α^+ M) naïve and N) total memory CD8⁺ T cells. P-Q) 706 Quantification of IFN- γ^+ P) naïve and Q) total memory CD8⁺ T cells. A-Q) P1 n=5, HC^A 707 n=8, HC^P n=11. J-K) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 708 Ordinary one-way ANOVA with Šidák's multiple comparisons test. R) Representative 709 histograms for dilution of Cell Proliferation Dye (CPD) eF450 in P1 or control CD8⁺ T 710 cells after 4 days of stimulation with anti-CD3/CD28 beads at 1:32 bead to cell ratio. S) 711 712 Quantification of percent divided CD8⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios. 713 Shown are technical duplicates.

Figure 5. P1 CD4⁺ T cells are hyperactive and exhibit enhanced effector function. 714 A) Quantification of frequency of CD4⁺ T cells in P1 and adult (HC^A) or pediatric (HC^P) 715 controls. B) Representative contour plot of naïve (N), central memory (CM), effector 716 memory (EM), and TEMRA CD4⁺ T cells in the patient and a control. Quadrants 717 718 corresponding to each subset are shown to the right. C-F) Quantification of C) naïve, D) 719 CM, E) EM, F) TEMRA CD4⁺ T cells from B). G) Representative Helios histograms for 720 CD4⁺ T cells in P1 and three controls compared to a fluorescence minus one (FMO) 721 control. Mean fluorescence intensities (MFI) are indicated. H) Quantification of Helios 722 MFI in different CD4⁺ T cell subsets. I) Representative contour plots for PD-1⁺ CD4⁺ T cells in P1 and a control. J) Quantification of I). K-V) PBMCs stimulated 4h with 723 724 PMA+ionomycin. K), M), O), Q), T) Representative contour plots for K) IL-2⁺ CD4⁺ M) IFN- γ^+ CD4⁺, O) TNF- α^+ CD4⁺, Q) IFN- γ^+ IL-4⁻ T_H1 and IFN- γ^- IL-4⁺ T_H2, T) IL-21⁺IL-9⁻ T_{FH} 725 and IL-21⁻IL-9⁺ T_H9 cells in P1 and a control. Quadrant identities are shown on the 726 727 bottom right. Frequencies corresponding to each guadrant are included to the top right of each panel. L), N), P), R-S), U-V) Quantification of L) IL-2⁺ CD4⁺, N) IFN-γ⁺ CD4⁺, P) 728 TNF- α^+ CD4⁺, R) T_H1, S) T_H2), U) T_H9, V) T_{FH} cells. A-H), K-V) P1 n=5, HC^A n=8, HC^P 729

It is made available under a CC-BY-NC-ND 4.0 International license .

n=11. I-J) P1 n=3, HC^A n=8. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Ordinary oneway ANOVA with Šidák's multiple comparisons test. W-Y) PBMCs stimulated with anti-CD3/CD28 beads at various bead to cell ratios for 4 days. W) T_H cytokines measured by LEGENDplex. X) Representative histograms for dilution of Cell Proliferation Dye (CPD) eF450 in P1 or control CD4⁺ T cells stimulated at 1:32 bead to cell ratio. Y) Quantification of percent divided CD4⁺ T cells at 1:8, 1:16, 1:32 bead to cell ratios. Shown are technical duplicates.

- 737 Figure 6. P1 Tregs have aberrant cytokine production and impaired suppressive
- function. A) Quantification of frequency of CD3⁺CD4⁺CD8⁻CD25⁺CD127¹⁰FOXP3⁺ 738 739 Tregs in P1 and adult (HC^A) or pediatric (HC^P) controls. B) Representative Helios histograms for Tregs in P1 and three controls compared to a fluorescence minus one 740 741 (FMO) control. Mean fluorescence intensities (MFI) are indicated. C) Quantification of Helios MFI in Tregs. D) CpG methylation of the Treg-specific demethylated region 742 (TSDR) for P1 or control Tregs and Tconvs. Percent methylation at different TSDR CpG 743 744 sites is indicated. Representative of n=2. E) Quantification of FOXP3 MFI in Tregs. F) 745 Quantification of PD-1⁺ Tregs. G-O) PBMCs stimulated 4h with PMA+ionomycin. G), I), 746 N) Representative contour plots for G) IL-2⁺, I) IFN- γ^+ , IL-4⁺, and N) TNF- α^+ Tregs. H), J-M), O) Quantification of H) IL-2⁺, J) IL-4⁺, K) IFN- γ^+ , L) IL-9⁺, M) IL-21⁺, O) TNF- α^+ 747 Tregs. A-C), E), J-O) P1 n=5, HC^A n= 10, HC^P n=12. F-H) P1 n=3, HC^A n=8. *p<0.05, 748 749 **p<0.01, ***p<0.001, ****p<0.0001. Ordinary one-way ANOVA with Šidák's multiple 750 comparisons test. P) Isolated and expanded Tregs stimulated with anti-CD3/CD28 751 beads for 4 days. T_H cytokines measured by LEGENDplex. Shown are 3 technical 752 replicates. Q-R) Isolated and expanded Tregs co-cultured at different ratios with control CD3⁺ T responder (Tresp) cells. n=2. Q-R) Suppression of Q) CD4⁺ and R) CD8⁺ T cell 753 754 proliferation. Significance determined by one-way ANOVA of areas under the curve. S) 755 T_H cytokines measured by LEGENDplex when co-culturing 1:16 bead:cell ratio stimulated P1 CD3⁺ Tresp with control Tregs. Shown are technical triplicates. 756

Figure 7. P1 naïve CD4⁺ T cells are more active and primed for effector function.
 A-E) Single-cell RNA sequencing (scRNA-seq) of sorted CD3⁺CD4⁺CD25⁺CD127^{lo}
 Tregs from P1 and 2 age-matched and sex-matched controls. A) Unstimulated Tregs

It is made available under a CC-BY-NC-ND 4.0 International license .

clustered and annotated using the DICE project and B) CD45RA/HLA-DR AbSeq 760 761 labelling. Panels represent the controls and P1 Tregs clustered together (overall) or 762 control or P1 Tregs alone. Included are legends with colours and numbers 763 corresponding to each cell type labelled. Doughnut plots are included below each panel 764 to represent the frequency of each annotated cell type. C-E) Volcano plots comparing stimulated patient and control C) CD45RA⁺HLA-DR⁻ naïve, D) CD45RA⁻HLA-DR⁺ 765 766 activated, and E) CD45RA⁻HLA-DR⁻ Tregs. Red=significantly increased, 767 blue=significantly decreased, gray=non-significant. Vertical dashed line: fold change=1.5, horizontal dashed line: FDR=0.05. Top 10 most significant genes are 768 labelled. F-H) scRNA-seq of sorted CD3⁺CD4⁺CD25⁻CD127^{hi} Tconv from P1 and 2 age-769 770 matched and sex-matched controls. F-G) Unstimulated Tconv clustered and annotated 771 as in A-B). H-I) Volcano plots as in C-E) comparing stimulated patient and control H) CD45RA⁺ naïve or I) CD45RA⁻ memory Tconvs. J) Gene set enrichment of differentially 772 773 expressed genes between stimulated naïve patient and control Tconvs using EnrichR. 774 Shown are the combined scores and adjusted p-values. H=MSigDB Hallmark, B=BioPlanet 2019, N=NCI Nature 2016, K=KEGG 2021 Human. K-P) PBMCs 775 stimulated 4h with PMA+ionomycin. Quantification of stimulated K) IL-2⁺ naïve, L) IL-2⁺ 776 total memory, M) IFN- γ^+ naïve, N) IFN- γ^+ total memory, O) TNF- α^+ naïve, and P) TNF- α^+ 777 total memory CD4⁺ T cells, K-P) P1 n=5, HC^A n=8, HC^P n=11, ***p<0.001, ****p<0.0001, 778 779 Ordinary one-way ANOVA with Šidák's multiple comparisons test.

Figure 1



Figure 2





0.5

Variant

WT

+

_

÷

+

+



Figure 4











It is made available under a CC-BY-NC-ND 4.0 International license .

Table 1

	Patient	Reference
	(0.5-5 yo)	(0.5-5 yo)
Lymphocytes (x10 ⁹ /L)	*1.31	2.00 – 8.00
CD3 ⁺ T cells	1.14	0.90 – 4.50
CD4 ⁺ T cells	0.74	0.50 – 2.40
CD8 ⁺ T cells	*0.19	0.30 – 1.60
CD19⁺ B cells	0.52	0.20 – 2.10
TREC (copy number / 3µL)	*3.08	>75
Red blood cells (x10 ¹² /L)	*2.83	3.90 – 5.30
Reticulocytes (x10 ⁹ /L)	32	20-80
Nucleated red blood cells (x10 ⁹ /L)	*0.05	<0.01
Platelets (x10 ⁹ /L)	383	200-490
Mean platelet volume (fL)	9.9	8.60 – 11.6
Neutrophils (x10 ⁹ /L)	3.07	1.50 – 8.50
Monocytes (x10 ⁹ /L)	0.54	0.00 – 0.90
Hemoglobin (g/L)	*103	105 – 135
Hematocrit	*0.30	0.33 – 0.39
Mean corpuscular volume	*104	75 – 87
Mean corpuscular hemoglobin	*36	24 – 30
Prothrombin time (s)	9.9	9.6 – 11.9
International normalized ratio	0.9	0.9 – 1.1
Lactate dehydrogenase (U/L)	640	500 – 920
Antibody Response		
IgG (g/L)	6.7 [‡]	4.0 - 8.3
IgA (g/L)	0.63	0.18 – 1.00
IgM (g/L)	0.83	0.19 – 1.46
IgE (μg/L)	*242	<18
Tetanus antitoxin (IU/mL)	0.83	0.10 – 1.00
Diptheria antitoxin (IU/mL)	0.70	0.50 – 1.10
DAT (polyspecific)	*Positive +3	Negative
Anti-IgG	*Positive +3	Negative
Anti-IgA	Negative	Negative
Anti-IgM	Negative	Negative
Anti-C3c	Negative	Negative
Anti-C3d	Negative	Negative
Hemoglobinopathy Workup		
HGB F	*0.044	0.000 - 0.011
HGB A	*0.831	0.848 - 0.920
HGB A2	0.029	0.022 - 0.034
BART's or HGB H Spike	Not detected	Not detected